Abstract
Recent interest in lung cancer without a history of tobacco smoking has led to the classification of a distinct disease entity of ‘non-smoking-associated lung cancer’. In this review article, we have made an overview of the recent literature concerning both the epidemiology and clinical features of lung cancer in never smokers, and have brought ‘non-smoking-associated lung cancer’ into relief. The etiology of lung cancer in never smokers remains indefinite although many putative risk factors have been described including secondhand smoking, occupational exposures, pre-existing lung diseases, diet, estrogen exposure, etc. Non-small cell lung cancer (NSCLC) in never smokers is clinically characterized by an increased incidence in females and a higher occurrence of adenocarcinoma in comparison to NSCLC in ever smokers in both surgical patients and non-resectable advanced-stage patients. Furthermore, the prognosis of never-smoking NSCLC is better than that of smoking-related NSCLC in both surgical patients and non-resectable advanced-stage patients. Recently recognized novel gene mutations such as EGFR (epidermal growth factor receptor) mutations are largely limited to never smokers or light smokers, and the expression of this gene is responsible for the clinical efficacy of gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor. NSCLC with the EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion gene is also more likely to occur in never smokers and in those with adenocarcinoma histology, and is expected to benefit from ALK inhibitors. In consideration of the future increase in never-smoking NSCLC or ‘non-smoking-associated lung cancer’, both clinical trials and investigations are needed.
Similar content being viewed by others
References
Wakelee HA, Chang ET, Gomez SL et al (2007) Lung cancer incidence in never smokers. J Clin Oncol 25:472–478
Boffetta P, Jarvholm B, Brennan P et al (2001) Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer 94:591–593
Toh CK, Gao F, Lim WT et al (2006) Never-smokers with lung cancer. Epidemiologic evidence of a distinct disease entity. J Clin Oncol 24:2245–2251
Koo LC, Ho JH (1990) Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 19:S14–S23
Colditz GA, Mason JE, Hankinson SE (1997) The Nurses’ Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6:49–62
Rimm EB, Stampfer MJ, Colditz GA et al (1990) Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. Am J Epidemiol 131:1068–1071
Bemstein L, Allen M, Anton-Culver H et al (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 13:625–635
Kolonel LN, Henderson BE, Hankin JH et al (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151:346–357
Haiman CA, Stram DO, Wilkens KR et al (2006) Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 354:333–342
Lamberg K, Wagenius G, Garmo H et al (2004) Lung cancer in the Uppsala/Orebro region: register for lung cancer: account of materials for 1995–2003. Regional Oncological Center, Uppsala, Sweden
Yong LC, Brown CC, Schatzkin A et al (1997) Intake of vitamins E, C, and A and risk of lung cancer: The NHANES I epidemiologic followup study. Am J Epidemiol 146:231–243
Freedman ND, Leitzmann MF, Hollenbeck AR et al (2008) Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 19:1391–1399
Thun MJ, Hannan LM, Adams-Campbell LL et al (2008) Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLOS Med 5:1357–1371
Brownson RC, Alavanja MCR, Caporaso N et al (1998) Epidemiology and prevention of lung cancer in nonsmokers. Epidemiol Rev 20:218–236
Zhong L, Goldberg MS, Parent M et al (2000) Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. Lung Cancer 27:3–18
Brennan P, Buffler PA, Reynolds P et al (2004) Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer 109:125–131
Kurahashi N, Inoue M, Liu Y et al (2008) Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 122:653–657
Zeka A, Mannetje A, Zaridze D et al (2006) Lung cancer and occupation in nonsmokers: a multicenter case-control study in Europe. Epidemiology 17:615–623
Brenner DR, Hung RJ, Tsao MS et al (2010) Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 10:285
Wu AH, Fontham ETH, Reynolds P et al (1995) Previous lung disease and lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 141:1023–1032
Liang HY, Li XL, Yu XS et al (2009) Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systemic review. Int J Cancer 125:2936–2944
Park JA, Park HJ, Lee JS et al (2008) Adenocarcinoma of lung in never smoked children. Lung Cancer 61:266–269
Okazaki H, Takayama S, Sugimura T (1991) Carcinogenicities of heterocyclic amines in cooked food. Mutat Res 259:399–410
Reinik M, Tamme T, Roasto M et al (2007) Polycyclic aromatic hydrocarbons (PHAs) in meat products and estimated PAH intake by children and the general population in Estonia. Food Addit Contam 24:429–437
Mirvish SS (1977) N-nitroso compounds: their chemical and in vitro formation and possible importance as environmental carcinogens. J Toxicol Environ Health 2:1267–1277
McCord JM (1998) Iron, free radicals, and oxidative injury. Semin Hematol 35:5–12
Hung X (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 533:153–171
Cross AJ, Leitzmann MF, Gail MH et al (2007) A prospective study of red and processed meat intake in relation to cancer risk. PloS Med 4:1973–1984
Tasevska N, Sinha R, Kipnis V et al (2009) A prospective study of meat, cooking methods, meat mutagens, heme iron, and lung cancer risks. Am J Clin Nutr 89:1884–1894
Stabile LP, Davis AL, Gubish CT et al (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptors alpha and beta and show biological responses to estrogen. Cancer Res 62:2141–2150
Raso MG, Behrens C, Herynk MH et al (2009) Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15:5359–5368
Nose N, Sugio K, Oyama T et al (2009) Association between estrogen receptor β expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27:411–417
Shimazu T, Inoue M, Sasazuki S et al (2010) Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am J Clin Nutr 91:722–728
Seow A, Koh WP, Wang R et al (2009) Reproductive variables, soy intake, and lung cancer risk among nonsmoking women in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 18:821–827
Kuiper GG, Lemmen JG, Carlsson B et al (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252–4263
Kohno T, Kakinuma R, Iwasaki M et al (2010) Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs. Carcinogenesis 31:1794–1799
Matakidou A, Eisen T, Bridle H et al (2005) Case-control study of familial lung cancer risks in UK women. Int J Cancer 116:445–450
Etzel CJ, Amos CI, Spitz MR (2003) Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Res 63:8531–8535
Lorenzo BJ, Hemminski K (2005) Familial lung cancer and aggregation of smoking habits: a simulation of the effect of shared environmental factors on the familial risk of cancer. Cancer Epidemiol Biomarkers Prev 14:1738–1740
Nitadori J, Inoue M, Iwasaki M et al (2006) Association between lung cancer incidence and family history of lung cancer. Chest 130:968–975
Okasaka T, Matsuo K, Suzuki T et al (2009) hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. J Hum Genet 54:739–745
Shih CM, Chen CY, Lee IH et al (2010) A polymorphism in the hMLH1 gene (−93G– > A) associated with lung cancer susceptibility and prognosis. Int J Mol Med 25:165–170
Yoon KA, Kim JH, Gil HJ et al (2008) CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 60:40–46
Yano T, Miura N, Takenaka T et al (2008) Never-smoking non-small cell lung cancer as a separate entity—the clinico-pathologic features and survival. Cancer 113:1012–1018
Zell JA, Ou SH, Ziogas A et al (2005) Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 23:8396–8405
Fujisawa T, Lizasa T, Saitoh Y et al (1999) Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 17:2086–2091
Sioris T, Husgafvel-Pursiainen K, Karjalainen A et al (2000) Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure. Int J Cancer 86:590–594
Tammenagi CM, Neslund-Dudas C, Simoff M et al (2004) Smoking and lung cancer survival. Chest 125:27–37
Nia PS, Weyler J, Colpaert C et al (2005) Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer 47:351–359
Yoshino I, Kawano D, Taro Oba et al (2006) Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg 81:1189–1193
Mitsudomi T, Tateishi M, Oka T et al (1989) Longer survival after non-small cell lung cancer in Japanese women. Ann Thorac Surg 48:639–642
Fu JB, Kau TY, Severson RK et al (2005) Lung cancer in women. Analysis of the national surveillance, epidemiology, and end results database. Chest 127:768–777
Perrot M, Licker M, Spiliopoulous A et al (2000) Sex differences in presentation, management and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 119:21–26
Ferguson MK, Wang J, Vokes E et al (2000) Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 69:245–250
Sekine Y, Suzuki H, Nakajima T et al (2010) Risk quantification for pulmonary complications after lung cancer surgery. Surg Today 40:1027–1033
Hanagiri T, Sugio K, Mizukami M et al (2008) Significance of smoking as a postoperative prognostic factor with non-small cell lung cancer. J Thorac Oncol 3:1127–1132
Subramanian J, Velcheti V, Gao F et al (2007) Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSLLC). J Thorac Oncol 2:827–830
Nordquist LT, Simon GR, Cantor A et al (2004) Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 126:347–351
Kawaguchi T, Takada M, kubo A et al (2010) Gender, histology, and time of diagnosis are important factors for prognosis. Analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 5:1011–1017
Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551
Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1479–1500
Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101:13306–13311
Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967
Jackman DM, Miller VA, Cioffredi LA et al (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267–5273
Kosaka T, Yatabe Y, Endoh H et al (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923
Satouchi M, Negoro S, Funada Y et al (2007) Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer 96:1191–1196
Lee YJ, Cho BC, Jee SH et al (2010) Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 28:487–492
Bai H, Mao L, Wang hS et al (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 27:2653–2659
Pham DK, Kris MG, Riely GJ et al (2006) Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24:1700–1704
Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566
Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275–4283
Wong DW, Leung EL, So KK et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723–1733
Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253
Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703
Conflict of interest
Y. Maehara has received research funding from Chugai Pharmaceutical and AstraZeneca. The others have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yano, T., Haro, A., Shikada, Y. et al. Non-small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: epidemiology and clinical features. Int J Clin Oncol 16, 287–293 (2011). https://doi.org/10.1007/s10147-010-0160-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0160-8